当前位置： SCI文献检索 > JOURNAL OF CLINICAL PHARMACOLOGY期刊下所有文献 > Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.

Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.

Abstract：

:The pharmacokinetics, pharmacodynamics, and safety of fosinopril sodium (SQ 28,555), a new orally active angiotensin-converting enzyme (ACE) inhibitor, was evaluated in 73 healthy men in two separate studies. In study I, doses ranging from 10 to 640 mg were administered once daily for 3 days to seven groups of five subjects each. Serum aldosterone levels, ACE activity, and sitting blood pressure were determined, as were pharmacokinetic parameters of fosinoprilat, the active diacid of fosinopril. In a dose-tolerance study (study II), 80 and 160 mg of the drug were administered in doses of 40 mg bid and 80 mg bid for 2 weeks. Pharmacokinetics were determined on days 1 and 14, and blood pressure and ACE activity were measured daily. One hour after all doses of fosinopril, serum ACE activity was undetectable. Peak blood levels of fosinoprilat occurred at about 3 hours after dosing, and linear kinetics of the diacid were observed. ACE activity remained undetectable for more than 24 hours after the treatment was stopped in study II. Serum aldosterone levels were decreased by 50% of baseline values in both studies. In study I, maximal reductions in mean blood pressure occurred approximately 6 hours postdose; once-daily doses of 20 mg or greater achieved reductions of 11.3 to 21.6% (P less than or equal to .05, compared with placebo reductions). Fosinopril was well tolerated. Subjects reported only mild gastrointestinal complications at doses of 80 mg/day or higher. These data show that fosinopril is a safe and effective inhibitor of ACE with a long duration of action on serum ACE activity.

journal_name

J Clin Pharmacol

journal_title

Journal of clinical pharmacology

authors

Duchin KL,Waclawski AP,Tu JI,Manning J,Frantz M,Willard DA

doi

10.1002/j.1552-4604.1991.tb01887.x

subject

Has Abstract

pub_date

1991-01-01 00:00:00

pages

58-64

issue

1

eissn

0091-2700

issn

1552-4604

journal_volume

31

pub_type

临床试验,杂志文章

相关文献

JOURNAL OF CLINICAL PHARMACOLOGY文献大全
  • Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.

    abstract：:The objective of this study was to determine the absolute oral bioavailability and disposition of omapatrilat. This single-dose, randomized, crossover study of 20 mg intravenous and 50 mg oral [14C]omapatrilat was conducted in 12 healthy male subjects to determine the disposition and oral bioavailability of omapatrila...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1177/00912700122010726

    authors： Malhotra BK,Iyer RA,Soucek KM,Behr D,Liao WC,Mitroka JG,Kaul S,Cohen MB,Knupp CA

    更新日期：2001-08-01 00:00:00

  • Clinical utility of ambulatory blood pressure monitoring in target organ complications and equipment choices.

    abstract：:Although population studies have demonstrated a relationship between casual office blood pressures and target organ events, the variability of these blood pressure measurements for individual patients has generated an interest in the role of ambulatory blood pressure monitoring for defining the presence of hypertensio...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,评审

    doi：10.1002/j.1552-4604.1992.tb05771.x

    authors： Prisant LM,Bottini PB,Carr AA

    更新日期：1992-07-01 00:00:00

  • Population Pharmacokinetics of Adjunctive Lacosamide in Pediatric Patients With Epilepsy.

    abstract：:A pediatric population pharmacokinetic model including covariate effects was developed using data from 2 clinical trials in pediatric patients with epilepsy (SP0847 and SP1047). Lacosamide plasma concentration-time data (n = 402) were available from 79 children with body weights ranging from 6 to 76 kg, and a balanced...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1340

    authors： Winkler J,Schoemaker R,Stockis A

    更新日期：2019-04-01 00:00:00

  • The effect of intravenous enalaprilat (MK-422) administration in patients with mild to moderate essential hypertension.

    abstract：:The antihypertensive effect of enalaprilat (MK-422), an intravenous (IV), nonsulfhydryl converting-enzyme inhibitor, was evaluated in a double-blind study of 14 patients with mild to moderate hypertension. The seven patients in the treatment group initially received IV enalaprilat 1.25 mg q6h for 24 hours. Thereafter,...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1002/j.1552-4604.1987.tb03041.x

    authors： Evans RR,Henzler MA,Weber EM,DiPette DJ

    更新日期：1987-05-01 00:00:00

  • Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.

    abstract：:Semagacestat, a γ-secretase inhibitor, reduces formation of amyloid beta peptide. Two single-dose (140 mg), open-label, randomized, 3-period, crossover studies evaluated the effect of formulation, food, and time of dosing on the pharmacokinetics and pharmacodynamics of semagacestat in healthy participants. The first s...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1177/0091270011407195

    authors： Willis BA,Zhang W,Ayan-Oshodi M,Lowe SL,Annes WF,Sirois PJ,Friedrich S,de la Peña A

    更新日期：2012-06-01 00:00:00

  • New pharmacokinetic methods: I. Estimation of mean serum concentration from trough serum concentration.

    abstract：:An equation is derived to estimate mean steady state serum concentration (Css) from trough steady state serum concentration (Cmin) which can be used for drugs with either linear or nonlinear pharmacokinetic properties. In 15 subjects receiving phenytoin monotherapy, estimated Css did not differ significantly from meas...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1990.tb03612.x

    authors： Browne TR,Greenblatt DJ,Szabo GK,Evans JE,Evans BA

    更新日期：1990-06-01 00:00:00

  • Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine.

    abstract：:Possible effects of multiple-dose administration of atorvastatin on the pharmacokinetics of single-dose antipyrine were evaluated in this drug-drug interaction study. Twelve healthy male volunteers received three 200-mg capsules of antipyrine on days 1 and 22, and two 40-mg atorvastatin tablets in the morning on days ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1996.tb04212.x

    authors： Yang BB,Hounslow NJ,Sedman AJ,Forgue ST

    更新日期：1996-04-01 00:00:00

  • Calcium channel blockade in experimental aminoglycoside nephrotoxicity.

    abstract：:Calcium channel blocker therapy has proved protective in certain models of ischemic-induced acute renal failure. This effect may be related to the prevention of calcium influx into injured cells or by the vasodilatory effects of verapamil that may result in an improvement in renal blood flow. In the current study, the...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1987.tb03076.x

    authors： Watson AJ,Gimenez LF,Klassen DK,Stout RL,Whelton A

    更新日期：1987-08-01 00:00:00

  • Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects.

    abstract：:The short-term effect of the blockade of the beta-adrenergic receptors on serum lipoproteins and the plasma activities of the enzymes involved in the metabolism of the serum lipoproteins: lipoprotein lipase (LPL), hepatic lipase (HL) and lecithin: cholesterol acyltransferase (LCAT) was evaluated in ten healthy normoli...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1987.tb03052.x

    authors： Harvengt C,Heller FR,Martiat P,Van Nieuwenhuyze Y

    更新日期：1987-07-01 00:00:00

  • Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers.

    abstract：:An open-label, randomized, crossover study was performed in healthy male volunteers to evaluate the potential pharmacokinetic and pharmacodynamic interactions and tolerability of single oral doses of modafinil (200 mg) and dextroamphetamine (10 mg). Blood samples were collected for determination of plasma levels of mo...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1002/j.1552-4604.1998.tb04395.x

    authors： Wong YN,Wang L,Hartman L,Simcoe D,Chen Y,Laughton W,Eldon R,Markland C,Grebow P

    更新日期：1998-10-01 00:00:00

  • Effects of esmolol on airway function in patients with asthma.

    abstract：:In a double-blind, randomized, crossover study in ten patients with asthma, the effects on specific airway resistance of esmolol, a new ultra-short-acting beta 1-selective adrenoceptor blocker, were compared with those of placebo. Specific airway resistance was measured during increasing doses of esmolol infusion, dur...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1002/j.1552-4604.1986.tb02929.x

    authors： Sheppard D,DiStefano S,Byrd RC,Eschenbacher WL,Bell V,Steck J,Laddu A

    更新日期：1986-03-01 00:00:00

  • Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

    abstract：:This analysis was conducted to characterize the pharmacokinetics and pharmacodynamics of pegfilgrastim and to develop a pharmacokinetic-pharmacodynamic model to describe the granulopoietic effects of pegfilgrastim and the homeostatic regulation of pegfilgrastim clearance in healthy subjects. Pegfilgrastim serum concen...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1177/0091270006288731

    authors： Roskos LK,Lum P,Lockbaum P,Schwab G,Yang BB

    更新日期：2006-07-01 00:00:00

  • Electrocardiographic effects of rivastigmine.

    abstract：:The electrocardiographic (ECG) effects of rivastigmine treatment were assessed in mild to moderately severe Alzheimer's disease (AD) by analysis of four 26-week, double-blind, multicenter, placebo-controlled, phase III clinical trials. Of an initial 2791 patients, 77% completed treatment. Seventy-one percent required ...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1177/00912700222011490

    authors： Morganroth J,Graham S,Hartman R,Anand R

    更新日期：2002-05-01 00:00:00

  • Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers.

    abstract：:The pharmacokinetics, safety, and tolerance of linopiridine ([3,3-bis(4-pyridinylmethyl)-1-phenylindolin-2-one]; DuP 996) a potential therapeutic agent for Alzheimer's disease, were assessed in double-blind, placebo-controlled, randomized studies in which single oral doses were given to 64 healthy young or elderly mal...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1002/j.1552-4604.1995.tb04741.x

    authors： Pieniaszek HJ Jr,Fiske WD,Saxton TD,Kim YS,Garner DM,Xilinas M,Martz R

    更新日期：1995-01-01 00:00:00

  • Influence of food on the oral absorption and bioavailability of moricizine.

    abstract：:Moricizine, a unique Class I antiarrhythmic agent, was orally administered with and without a meal to 24 healthy male subjects to determine the effect of food on moricizine absorption and bioavailability. Relative to the fasting state, a standardized breakfast delayed the time to peak plasma moricizine concentration (...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1991.tb01912.x

    authors： Pieniaszek HJ Jr,Rakestraw DC,Schary WL,Williams RL

    更新日期：1991-09-01 00:00:00

  • A model for estimating individualized valproate clearance values in children.

    abstract：:To evaluate the population pharmacokinetics of valproic acid in children, 97 steady-state serum valproate concentration measurements were gathered during normal, routine, outpatient care of 52 children with epilepsy (1.2-16 years of age). Levels were obtained from patients receiving valproate monotherapy (49%) or valp...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1995.tb04020.x

    authors： Botha JH,Gray AL,Miller R

    更新日期：1995-10-01 00:00:00

  • The metabolism of floctafenin in man and rodents.

    abstract：:Floctafenin (FFn), 2,3-dihydroxypropyl--N--(8--trifluoromethyl--4--quinolyl) anthranilate, a new nonnarcotic analgesic drug, was studied in man, mice, and the isolated perfused rat liver. In all species the drug is rapidly hydrolyzed to floctafenic acid (FFa). In seven volunteer subjects who each received a single ora...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1979.tb01613.x

    authors： Lynn RK,Holm R,Swanson BN,Smith R,Gerber N

    更新日期：1979-01-01 00:00:00

  • Metabolic effects of the combination of captopril and hydrochlorothiazide in hypertensive subjects.

    abstract：:The medium-term (16 weeks) effects of the combination of captopril and hydrochlorothiazide (HCTZ) on some metabolic indexes, particularly on plasma lipoproteins, were evaluated in 20 mild to moderate hypertensive outpatients. After a 4-week wash-out period, the subjects were given one tablet of a new commercially avai...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1990.tb03590.x

    authors： Perani G,Martignoni A,Muggia C,Ferrari T,Simonich P,Pompei R,Marchesi E,Finardi G

    更新日期：1990-11-01 00:00:00

  • Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.

    abstract：:This study assessed the efficacy and safety of ketoprofen patch compared with placebo in patients who had rheumatoid arthritis and persistent wrist pain. Patients (N = 676)who had achieved systemic disease control with a disease-modifying antirheumatic drug and/or systemic corticosteroid, but still had persistent wris...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1177/0091270009355813

    authors： Kawai S,Uchida E,Kondo M,Ohno S,Obata J,Nawata Y,Sugimoto K,Oribe M,Nagaya I

    更新日期：2010-10-01 00:00:00

  • Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.

    abstract：:The cytomegalovirus (CMV) viral terminase inhibitor letermovir is indicated for prevention of CMV infection in CMV-seropositive allogeneic hematopoietic stem cell transplant recipients. In this analysis, functional variants in solute carrier organic anion transporter family member 1B1 (SLCO1B1), uridine diphosphate-gl...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1420

    authors： Kobie J,Guo Z,Cho CR,Menzel K,McCrea JB,Blanchard R,Shaw PM

    更新日期：2019-09-01 00:00:00

  • Optimization of sampling time for cyclosporine monitoring in transplant patients.

    abstract：:Cyclosporine (CsA) dosing is based on CsA plasma or blood concentrations measured 12 to 24 hours after drug administration (trough levels). This study evaluated the relationship between the timing of CsA concentrations and subsequent pharmacokinetic parameters to predict an optimal sampling period. Plasma samples were...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1992.tb03798.x

    authors： Regazzi MB,Rondanelli R,Gastaldi L,Martinelli L,Viganò M

    更新日期：1992-11-01 00:00:00

  • Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters.

    abstract：:A general objective of drug-drug interaction (DDI) studies is to determine whether potential interactions of new molecular entities with concomitantly administered other drugs exist and, if DDIs occur, whether dosage adjustments are required. A typical end point for DDI evaluations is the ratio of area under the plasm...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1104

    authors： Yamazaki S

    更新日期：2018-08-01 00:00:00

  • Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.

    abstract：:Argatroban, a direct thrombin inhibitor, is metabolized in vitro by CYP3A4/5 and therefore may be susceptible to clinically relevant CYP3A drug interactions. The effect of erythromycin, a potent CYP3A4/5 inhibitor, on the pharmacokinetics and pharmacodynamics of argatroban was evaluated in 14 healthy male volunteers i...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：

    authors： Tran JQ,Di Cicco RA,Sheth SB,Tucci M,Peng L,Jorkasky DK,Hursting MJ,Benincosa LJ

    更新日期：1999-05-01 00:00:00

  • Target-Mediated Drug Disposition-A Class Effect of Soluble Epoxide Hydrolase Inhibitors.

    abstract：:Pharmacological target-mediated drug disposition (TMDD) represents a special source of nonlinear pharmacokinetics, and its occurrence in large-molecule compounds has been well recognized because numerous protein drugs have been reported to have TMDD due to specific binding to their pharmacological targets. Although TM...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1763

    authors： An G,Lee KSS,Yang J,Hammock BD

    更新日期：2020-10-19 00:00:00

  • Effects of Adding Pentoxifylline to Captopril on Primary Hypertension: A Pilot Randomized Clinical Trial.

    abstract：:Because of the key role blood viscosity plays in the regulation of blood pressure (BP) and the hemorheological effects of pentoxifylline (PTX), this study was conducted to evaluate whether PTX can reduce BP when added to captopril in patients with stage 1 hypertension. In this randomized clinical trial 62 patients wit...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1516

    authors： Namdar H,Khani E,Pourrashid MH,Entezari-Maleki T

    更新日期：2020-02-01 00:00:00

  • Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function.

    abstract：:Following oral administration of a single 500-mg dose of cefalexin, serum and urine levels of the antibiotic were determined comparatively in ten normal subjects, ten patients with renal impairment, and ten patients with chronic nephritis on maintenance hemodialysis. In normal subjects, mean serum peak levels (12.0 +/...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1975.tb05918.x

    authors： Brogard JM,Pinget M,Dorner M,Lavillaureix J

    更新日期：1975-10-01 00:00:00

  • FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.

    abstract：:Recent advances in in vitro metabolism methods have led to an improved ability to predict clinically relevant metabolic drug-drug interactions. To address the relationships of in vitro metabolism data and in vivo metabolism outcomes, the Office of Clinical Pharmacology and Biopharmaceutics in the Center for Drug Evalu...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1177/00912709922008515

    authors： Davit B,Reynolds K,Yuan R,Ajayi F,Conner D,Fadiran E,Gillespie B,Sahajwalla C,Huang SM,Lesko LJ

    更新日期：1999-09-01 00:00:00

  • Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia.

    abstract：:Lormetazepam, an investigational hypnotic, was evaluated for efficacy and withdrawal phenomena in doses of 0.5, 1.0, 1.5, and 2.0 mg in four separate sleep laboratory protocols, each including four placebo baseline nights, seven drug nights, and three placebo withdrawal nights. A moderate degree of efficacy was shown ...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1002/j.1552-4604.1982.tb02645.x

    authors： Kales A,Bixler EO,Soldatos CR,Mitsky DJ,Kales JD

    更新日期：1982-11-01 00:00:00

  • Lofexidine in the treatment of hypertension: a twice-daily versus one-daily dose comparison with 24-hour blood pressure monitoring.

    abstract：:Lofexidine, an antihypertensive imidazoline derivative, was given to ten hypertensives on both a twice-daily and once-daily regimen, using routine blood pressure measurements and 24-hour Remler recording. Plasma renin activity and catecholamines were measured. After a dose titration with twice-daily doses, the total t...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1981.tb05697.x

    authors： Garrett BN,Kaplan NM

    更新日期：1981-04-01 00:00:00

  • Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.

    abstract：:Aprepitant or its prodrug fosaprepitant, in combination with a corticosteroid and a 5-HT(3) receptor antagonist, are used to prevent chemotherapy-induced nausea and vomiting. This study evaluated the effect of fosaprepitant 150 mg on CYP3A4 metabolism. Fosaprepitant 150 mg has been submitted to regulatory agencies for...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1177/0091270010387792

    authors： Marbury TC,Ngo PL,Shadle CR,Jin B,Panebianco D,Caro L,Valentine J,Murphy G

    更新日期：2011-12-01 00:00:00